Augmenix Snags $6.1M

Xconomy Boston — 

Waltham, MA-based Augmenix, the maker of implantable material to minimize the side effects of radiation therapy, said today it has closed a Series B round of financing worth $6.1 million. Ascension Health Ventures led the round, and was joined by Versant Ventures, Pinnacle Ventures, Catalyst Health Ventures, and several private investors, the company said. The company plans to use the money for clinical and commercial development of its SpaceOAR System in the U.S. and Europe, and to develop other products in its pipeline.